{
  "docId": "019dd923-5ca1-7489-b638-42055a53b541",
  "docSlug": "1774c324fda45105",
  "documentTitle": "Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report",
  "authorId": "LEK",
  "authorName": "L.E.K.",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 25,
  "pageCount": 58,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "industry_trends",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "Uses a 'Past vs Future' transformation framework to illustrate strategic shift.",
  "elementsJson": [
    "headline_text",
    "bullet_list",
    "process_diagram",
    "quote_block",
    "icon_grid"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b638-42055a53b541/25",
  "deckHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-25",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "With more innovative products being launched, market focus has shifted from previous “quick and successful launch” to “commercially attractive” as it directly decides a product’s ultimate success under increasingly homogeneous competition.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbd-8446c30bb50f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.36,
        "x": 0.61,
        "y": 0.31
      },
      "kind": "list",
      "text": "With more innovative products being launched, market focus has shifted from previous “quick and successful launch” to “commercially attractive” as it directly decides a product’s ultimate success under increasingly homogeneous competition",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "72ae483b-e75a-4fc4-a942-e2e927a15014",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.36,
        "x": 0.61,
        "y": 0.51
      },
      "kind": "list",
      "text": "More importantly, commercially attractive products better ensure company’s continuous future development: Sustainable fund for future innovative research; Strong valuation to attract future external investment; Successful transition from biotech towards biopharma",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec35b4bd-1362-469d-9ef9-a2cfc04a61e7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.03,
        "y": 0.21
      },
      "kind": "paragraph",
      "text": "Key considerations of drug R&D for pharma companies",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6f8bb66f-0664-4ded-af69-ed9a11a950ad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.4,
        "x": 0.15,
        "y": 0.67
      },
      "kind": "quote",
      "text": "… Commercial attractiveness including ability to tackle unmet needs, number of suboptimal treatment, ROI, etc. will be company’s top focus as investors will only have confidence to invest in companies that can be self-sustained during the entire life cycle, from R&D to commercialization …",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b03bc6a9-3ece-4277-9195-bdae24543276",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.4,
        "x": 0.15,
        "y": 0.31
      },
      "kind": "quote",
      "text": "… Companies with multiple pipeline or marketed products are more attractive to the capital market, leading to more PEVC support and easier IPO, thus companies tend to accelerate product launch through mature path to reduce risks and cater to market’s preference …",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cb08d865-e272-413a-9029-de40daaa8fbb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "… Commercial attractiveness including ability to tackle unmet needs, number of suboptimal treatment, ROI, etc. will be company’s top focus as investors will only have confidence to invest in companies that can be self-sustained during the entire life cycle, from R&D to commercialization … - CEO, a Chinese biotech, Oct. 2022",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbd-895548f6550c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.03,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Source: L.E.K. interviews and analysis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "81093305-624d-4793-aa2a-288fd0955367",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.95,
        "x": 0.03,
        "y": 0.09
      },
      "kind": "title",
      "text": "In future, commercial attractiveness is expected to become more of a key consideration for drug R&D",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6f7af54c-7a3a-4a5f-a177-2a9d69ca6717",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.45,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Increasing Focus of More Commercially Attractive Development Areas",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "46c1c208-8efe-4dab-ae52-b4d7d7cd65af",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "before-after-framing",
      "slug": null,
      "matchId": "027a0d0b-5eb2-4678-ad73-e7c995e3c223",
      "evidence": "Contrasts 'Past' (quick launch) with 'Future' (commercial attractiveness) to show strategic evolution.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}